Medical Research & News

Through a collaborative approach to research support, the Foundation is focused on improving diagnosis, treatment therapies, better understanding of the disease burden, and advocating for increased research funding that can benefit patients --- with an ultimate goal of helping researchers find a cure for cutaneous lymphoma.

FLASH Study

FLASH (Fluorescent Light Activated Synthetic Hypericin) is a potential new treatment for early stage cutaneous lymphoma using visible fluorescent light pursuing a New Drug Application (NDA) filing in the United States

TELLOMAK Study

A study evaluating the efficacy and safety of a monoclonal antibody called lauctamab - alone or in combination with chemotherapy - in patients with advanced T-cell lymphoma.

EORTC-CLG Annual Scientific Meeting Highlights

October 2021 - Highlights from the 2021 EORTC-CLG Scientific Meeting clinical presentations

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR®

April 2020 - Helsinn Therapeutics (U.S.), Inc., the US subsidiary of the Swiss pharmaceutical group focused on building quality cancer care products, today announces a change to the financial assistance program for VALCHLOR® (mechlorethamine) gel 0.016% to ensure that commercially insured patients have access to treatment during the COVID-19 crisis.

American Society of Hematology Announces 2020 Scholar Award Recipients

December 2019 - The American Society of Hematology (ASH) announced the 39 recipients of its 2020 Scholar Awards. One of ASH’s most prestigious research award programs, the ASH Scholar Awards financially support fellows to junior faculty dedicated to careers in hematology research as they transition from training programs to careers as independent investigators. Awardees included cutaneous lymphoma researcher, Anjali Mishra, PhD. 

FDA Approves Mogamulizumab for CTCL

The FDA has approved mogamulizumab-kpkc (Poteligeo) for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy.

Research in Cutaneous Lymphoma: A Broad View

Since the development of the “scientific method,” people have been engaged in research in efforts to answer questions, solve problems, and add to our overall knowledge. Nowhere is this more evident than in the medical field, and in the study of cutaneous lymphoma.

Protein Can Help Identify Which Rashes Are Early Mycosis Fungoides

Chronic rash in a sun-protected area that doesn’t respond to topical treatment likely needs to be evaluated for mycosis fungoides, the most common variant of cutaneous T-cell lymphoma. Now, a new VA study reports that a protein expression can help make the diagnosis.

Skin-Directed Tactics Optimal for Early Cutaneous Lymphoma

For patients with early-stage cutaneous lymphoma, skin-directed treatments, such as topical steroids and phototherapy, can slow or halt progression, but patients are also being treated with systemic therapies, according to the first-of-its kind research on this rare malignancy.

FUTURE DIRECTIONS IN T-CELL CUTANEOUS LYMPHOMA

Advances are being made in improving diagnostic tools. Dr. Christiane Quelfeld presents what has become available and what the future holds.

WHAT ARE FOCUS AREAS IN CUTANEOUS LYMPHOMA RESEARCH?

New breakthroughs in research offer hope of better treatments and may offer insight into the causes of cutaneous lymphoma.

Modernizing Immunotherapy for Cutaneous T-cell Lymphoma

For decades, immunotherapy has been a cornerstone of systemic therapy for cutaneous T cell lymphoma (CTCL). It is therefore not surprising that modern immune-therapies, which target anti-tumor immunity in more sophisticated ways, have the potential to greatly improve our treatments for CTCL. 

Epigenetics & Biology of Cutaneous T-cell Lymphomas

These are exciting times in cutaneous T-cell lymphoma (CTCL) research. The hard work of laboratory and clinical investigators worldwide is starting to bear fruit, and a number of basic discoveries in the genetic and epigenetic foundations of CTCL are now being translated into novel therapies, with great impact for patients.

Medical Meeting Highlights: 3rd World Congress, T-Cell Lymphoma Forum and USCLC Annual Workshop

In a world that has 7,000 known rare diseases, with only 5% having any treatment available, the future of discovery and new treatment development in cutaneous lymphoma is promising. There is much hope for a brighter future for everyone living with this condition.